Clinical application of a new latex photometric immunoassay reagent, LPIA-GENESIS D-dimer, and its performance in patient-derived plasma samples
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
Authors: Nagahama, Yutaka; Nozaki, Junko; Sakurai, George; Yajima, Satoshi; Kaneko, Noriko; Yamazaki, Etsuko; Matsuda, Michio
Abstract
Introduction We previously reported an antibody MIF-220 that recognizes a specific structure induced on the surface of thrombin-activated E-domain of one fibrin molecule bound with the D-domains of other fibrinogen/fibrin molecules. Utilizing MIF-220, we produced a test kit for cross-linked fibrin degradation products (XDP), LPIA-GENESIS D-dimer (LG-DD), and evaluated basic performance characteristics for clinical application. We then attempted to apply LG-DD to see its eligibility in clinical plasma samples. Method The characteristic performances requested for clinical use were studied including limit of quantitation, within-run imprecision, day-to-day imprecision, antigen excess, interference study, and method comparison with LPIAACE-Ddimer (ACE-DD) available on the market. Results The performance characteristics were all satisfactory. Extraordinarily high concentrations of XDP are occasionally obtained by ACE-DD in samples with collection problems, but not by LG-DD, indicating that a certain XDP species present in the former was not measured by LG-DD. Structural studies suggested that the "B-b" set of polymerization sites must be involved as well in the maintenance of cross-linked fibrin in vivo. Conclusion LG-DD was able to measure a wide range of XDP, that is, 0.20-35.0 mu g FEU/mL that covers the levels of XDP in most of the clinical samples. LG-DD was found to almost avoid false-positive results noticed in samples as mentioned above, and this feature seems to be preferable to established kits for the measurement of XDP.
An association between N-terminal pro-brain natriuretic protein level and risk of left ventricular hypertrophy in patients without heart failure
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Authors: Huang, Lei; Huang, Longfei; Yu, Jing; Wu, Xianming; Zhao, Jinyan
Abstract
The objective of the present study was to investigate the association between N-terminal-pro-brain natriuretic peptide (NT-proBNP) quartiles and the risk of left ventricular hypertrophy (LVH), as well as to assess the association between NT-proBNP and hallmarks of LVH in heart failure (HF)-negative patients. Logistic regression analysis was used to analyze four groups of participants, who were stratified according to NT-proBNP quartiles, in order to investigate the association between NT-proBNP and the risk of LVH. Subsequently, analyses involving uni- and multivariate linear regression were performed to evaluate the associations of NT-proBNP with LV mass (LVM), LVM index (LVMI) and relative wall thickness (RWT). The results indicated that the occurrence of LVH was progressively enhanced along with increasing NT-proBNP quartiles in patients without HF. The univariate logistic regression analysis revealed that the groups of quartiles 4 and 3 carried a 5.254 and 1.757 times greater risk of LVH than the group of the lowest NT-proBNP quartile, respectively. Furthermore, the multivariate logistic regression analysis indicated that, compared with the quartile 1 group, participants in quartiles 2-4 had a significantly increased risk of LVH. In addition, significant positive linear associations of Lg(NT-proBNP) with LVM and LVMI were determined, while a inverse association between Lg(NT-proBNP) and RWT was indicated. The results of the present study suggested that the risk of LVH increased progressively with increasing NT-proBNP quartiles. On the basis of these results, NT-proBNP may be an effective independent prognostic marker for the risk of LVH in patients without HF.